---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-407728"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2026-09-29T21:00:13+00:00"
generated_at: "2026-10-12T13:52:44.220598+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics licenses Long Grove products for US sale; pays undisclosed milestones and royalties

## Summary
- Sept 23, 2026 Development and License Agreement with Long Grove Pharmaceuticals, LLC and Capstone Development Services Company, LLC.
- Heron gets exclusive (as to licensed patents), sublicensable US rights to import, distribute, sell and market certain products.
- Heron also gets a non-exclusive worldwide license to manufacture those products for sale in the Territory.
- Heron owes regulatory milestone payments, sales-based milestones, royalties and expense reimbursement; no dollar amounts were disclosed.
- Initial 10-year term from first commercial sale, automatic 2-year renewals; agreement to be filed with the Q3 2026 Form 10-Q.

## SEC filing metadata
- accession: 0001193125-26-407728
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2026-09-29T21:00:13+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000119312526407728/0001193125-26-407728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000119312526407728/hrtx-20260923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-407728
- JSON: https://secwatch.observer/filing/0001193125-26-407728.json
- Plain text: https://secwatch.observer/filing/0001193125-26-407728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.